Alyeska Investment Group
IGMS

Alyeska Investment Group’s IGM Biosciences IGMS Stock Holding History

Alyeska Investment Group’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-47,134
Closed -$837K – 449
2019
Q3 		$837K Buy
+47,134
New +$951K 0.01% 334

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alyeska Investment Group's IGMS Position: Q4 2019 in Review

Alyeska Investment Group sold out of IGM Biosciences (IGMS) in Q4 2019, closing a stake of 47,134 shares — an estimated $837K sold.

Alyeska Investment Group first reported a position in IGMS in Q3 2019 and held it in 1 quarter. The position peaked at $837K in Q3 2019. 50 funds tracked by Wall St. Rank hold IGMS as of Q4 2019.

  • Alyeska Investment Group reported no remaining IGM Biosciences position as of Q4 2019 after selling out during the quarter.
  • Alyeska Investment Group sold 47,134 IGM Biosciences shares in Q4 2019, an estimated $837K.
  • Alyeska Investment Group first reported a position in IGM Biosciences in Q3 2019 and held it in 1 quarter.
  • Alyeska Investment Group's IGM Biosciences position peaked at $837K in Q3 2019.
  • 50 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2019.

Based on Alyeska Investment Group's 13F filing for Q4 2019, filed 14 Feb 2020.